A Phase 3 interventional study of migalastat HCl 150 mg in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 6 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 11 in phase 3, and was the 18th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2019.
This study's enrollment of 16 is below the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
26 studies in Fabry Disease by BioMarin Pharmaceutical: 3 open now, 4 under way, 2 of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 20th registered.
BioMarin Pharmaceutical’s Fabry Disease studies by the year they started, since 2006.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
Among BioMarin Pharmaceutical’s 26 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl will be administered every other day (QOD) during the treatment period.
Drug: migalastat HCl 150 mg
migalastat HCl 150 mg capsule
Also known as: migalastat, AT1001
Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug
Number of subjects with TEAE, SAE, and AE leading to discontinuation during the study period
Time frame: Entire study
Change From Baseline to Month 24 in Estimated Glomerular Filtration Rate (eGFR)
Estimated GFR was calculated using the modified Schwartz formula according to the standards of the central laboratory.
Time frame: Baseline, Month 24
Change From Baseline to Month 24 in Urine Protein Levels
Renal function was assessed by urine protein levels (mg/L). Urine samples were collected as part of urinalysis.
Time frame: Baseline, Month 24
Change From Baseline to Month 24 in Urine Albumin
Renal function was assessed by urine albumin levels (mg/L). Urine samples were collected as part of urinalysis
Time frame: Baseline, Month 24
Change From Baseline to Month 24 in Left Ventricular Mass Index (LVMi)
LVMi was assessed as a measure of cardiac impairment in the study participants. LVMi values for both M-mode and 2D views are presented.
Time frame: Baseline, Month 24
Change From Baseline to Month 24 in Pediatric and Quality of Life Inventory™ (PedsQL™) Scores
The Pediatric Quality of Life Inventory (PedsQL™) was a modular approach to measuring health-related quality of life (QoL) in healthy children and adolescents and those with acute and chronic health conditions. All components of the PedsQL were scored based on a scale of 0 (never) to 4 (almost always) and linearly transformed to a 0 to 100 scale as follows: 0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0. Psychosocial, physical, and total scores were calculated based on the response to the questions within the patient reported outcome. The psychosocial score for the PedsQL encompassed 15 questions relating to the subjects' feelings, social interaction with others, and school. The physical score was derived from answers to 8 questions about the subjects' ease of managing physical activity. Total scores were the sum of all the item scores over the number of items answered on all the scales. Change from baseline values of \<0 represents worsening, 0 equals no change, and \>0 represents improvement.
Time frame: Baseline, Month 24
Change From Baseline to Month 24 in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) Score for Pain Intensity
The Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ) included questions about Fabry disease-specific symptoms. The assessment of "How bad is your pain today?" was measured on a 10- point scale from 0 (no pain) to 10 (pain as bad as you can imagine). A decrease from baseline indicates an improvement in the condition.
Time frame: Baseline, Month 24
Number of Subjects Who Experienced Sudden Onset of Pain As Assessed Using the Fabry-Specific Health and Pain Questionnaire (FPHPQ)
Subjects were asked "In the last 3 months how many times did you experience sudden onset of pain?" and responses were reported in the FPHPQ. Responses were categorized as 0, 1 to 3, 4 to 6, and \> 6 occurrences of sudden onset of pain.
Time frame: Month 24
Change From Baseline to Month 24 in Plasma Levels of Lyso-Gb3
Blood samples were collected for measurement of lyso-Gb3 levels in plasma. Plasma levels of lyso-Gb3 were measured using a validated liquid chromatography-mass spectrometry assay.
Time frame: Baseline, Month 24
| Milestone | Migalastat HCl 150 mg |
|---|---|
| Started | 16 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Number of subjects with TEAE, SAE, and AE leading to discontinuation during the study period
| Participants | Migalastat HCl 150 mg |
|---|---|
| Number of subjects with TEAEs | 13 |
| Number of subjects with SAE | 1 |
| Number of subjects with AE leading to discontinuation | 0 |
Estimated GFR was calculated using the modified Schwartz formula according to the standards of the central laboratory.
| mL/min x 1.73 m2 | Migalastat HCl 150 mg |
|---|---|
| Change From Baseline to Month 24 in Estimated Glomerular Filtration Rate (eGFR) | -27.6 ± 8.88 |
Renal function was assessed by urine protein levels (mg/L). Urine samples were collected as part of urinalysis.
| mg/L | Migalastat HCl 150 mg |
|---|---|
| Change From Baseline to Month 24 in Urine Protein Levels | 38.6 ± 79.03 |
Renal function was assessed by urine albumin levels (mg/L). Urine samples were collected as part of urinalysis
| mg/L | Migalastat HCl 150 mg |
|---|---|
| Change From Baseline to Month 24 in Urine Albumin | -12.7 ± 21.73 |
LVMi was assessed as a measure of cardiac impairment in the study participants. LVMi values for both M-mode and 2D views are presented.
| g/m2 | Migalastat HCl 150 mg |
|---|---|
| 2D-mode View | 4.75 ± 16.679 |
| M-mode View | 6.01 ± 9.014 |
The Pediatric Quality of Life Inventory (PedsQL™) was a modular approach to measuring health-related quality of life (QoL) in healthy children and adolescents and those with acute and chronic health conditions. All components of the PedsQL were scored based on a scale of 0 (never) to 4 (almost always) and linearly transformed to a 0 to 100 scale as follows: 0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0. Psychosocial, physical, and total scores were calculated based on the response to the questions within the patient reported outcome. The psychosocial score for the PedsQL encompassed 15 questions relating to the subjects' feelings, social interaction with others, and school. The physical score was derived from answers to 8 questions about the subjects' ease of managing physical activity. Total scores were the sum of all the item scores over the number of items answered on all the scales. Change from baseline values of \<0 represents worsening, 0 equals no change, and \>0 represents improvement.
| score on a scale | Migalastat HCl 150 mg |
|---|---|
| Psychosocial Score | 0 (-10 to 28) |
| Physical Score | 0 (-19 to 19) |
| Total Score | -1.1 (-9 to 25) |
The Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ) included questions about Fabry disease-specific symptoms. The assessment of "How bad is your pain today?" was measured on a 10- point scale from 0 (no pain) to 10 (pain as bad as you can imagine). A decrease from baseline indicates an improvement in the condition.
| score on a scale | Migalastat HCl 150 mg |
|---|---|
| Change From Baseline to Month 24 in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) Score for Pain Intensity | -1.3 ± 3.20 |
Subjects were asked "In the last 3 months how many times did you experience sudden onset of pain?" and responses were reported in the FPHPQ. Responses were categorized as 0, 1 to 3, 4 to 6, and \> 6 occurrences of sudden onset of pain.
| Participants | Migalastat HCl 150 mg |
|---|---|
| No occurrences | 3 |
| 1 to 3 occurrences | 4 |
| 4 to 6 occurrences | 0 |
| >6 occurrences | 1 |
Blood samples were collected for measurement of lyso-Gb3 levels in plasma. Plasma levels of lyso-Gb3 were measured using a validated liquid chromatography-mass spectrometry assay.
| ng/mL | Migalastat HCl 150 mg |
|---|---|
| Change From Baseline to Month 24 in Plasma Levels of Lyso-Gb3 | 0.05 ± 1.127 |
Collected over Adverse event data collected over duration of the study. Duration of participation varied by patient (range: 181 to 1457 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Migalastat HCl 150 mg | 0/16 (0%) | 1/16 (6.3%) | 13/16 (81.3%) |
| Event | Migalastat HCl 150 mg |
|---|---|
| GastroenteritisInfections and infestations | 1/16 |
| Event | Migalastat HCl 150 mg |
|---|---|
| Covid-19Infections and infestations | 3/16 |
| NasopharyngitisInfections and infestations | 3/16 |
| Aspartate aminotransferase increasedInvestigations | 3/16 |
| DizzinessNervous system disorders | 3/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/16 |
| Blood bilirubin increasedInvestigations | 2/16 |
| ParaesthesiaNervous system disorders | 2/16 |
| DiarrhoeaGastrointestinal disorders | 2/16 |
| Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/16 |
| Raynaud's phenomenonVascular disorders | 1/16 |
| Age, Customized(Participants) | Migalastat HCl 150 mg |
|---|---|
| 12 to < 16 years | 7 |
| 16 to < 18 years | 9 |
| Sex: Female, Male(Participants) | Migalastat HCl 150 mg |
|---|---|
| Female | 6 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Migalastat HCl 150 mg |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Migalastat HCl 150 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 15 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Prior Enzyme Replacement Therapy (ERT) status(Participants) | Migalastat HCl 150 mg |
|---|---|
| ERT-experienced | 8 |
| ERT-naive | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Nov 2024, 61 months.
Results were first posted in Jun 2025, 6 months after primary completion.
Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 61 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat